This white paper provides an in-depth analysis of antibody-drug conjugates (ADCs) as a rapidly advancing class of targeted cancer therapies. It reviews ADC structure, mechanisms of action, and technological evolution across four generations. Using IQVIA Ark Patent Intelligence, the report maps the global ADC pipeline, patent landscape, and competitive dynamics. Case studies of leading ADCs highlight strategic insights around innovation and differentiation. The paper concludes that continued advances in linkers, payloads, and targeting are positioning ADCs as a cornerstone of precision oncology.

Join for free to read